2019
MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma
MYTSYK, Yulian, Yuriy BORYS, Lesia TUMANOVSKA, Dmytro STROY, Askold KUCHER et. al.Základní údaje
Originální název
MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma
Autoři
MYTSYK, Yulian (804 Ukrajina), Yuriy BORYS (804 Ukrajina), Lesia TUMANOVSKA (804 Ukrajina), Dmytro STROY (804 Ukrajina), Askold KUCHER (804 Ukrajina), Katarina GAZDIKOVA (703 Slovensko), Luis RODRIGO (724 Španělsko), Peter KRUŽLIAK (703 Slovensko, garant, domácí), Robert PROSECKY (203 Česká republika), Peter URDZIK (703 Slovensko) a Victor DOSENKO (804 Ukrajina)
Vydání
Clinical and Experimental Medicine, Milan, SPRINGER-VERLAG ITALIA SRL, 2019, 1591-8890
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30101 Human genetics
Stát vydavatele
Itálie
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.644
Kód RIV
RIV/00216224:14110/19:00111783
Organizační jednotka
Lékařská fakulta
UT WoS
000491035600013
Klíčová slova anglicky
Cancer; Renal cell carcinoma; Clear cell; miRNA-15a; MicroRNA-15a; Biomarker; Genetic; Prediction; Prognosis; Survival
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 19. 12. 2019 08:20, Mgr. Tereza Miškechová
Anotace
V originále
None of the currently investigated molecular markers demonstrated sufficient accuracy in prognostication of the renal cell carcinoma (RCC) oncologic outcomes; thus, none of them has been recommended for the application in the routine clinical practice. The role of miR-15a as a potential prognostic marker for RCC is still not unveiled. The aim of our study was to assess the expression of miR-15a in tumor tissues of the patients with RCC and to evaluate the possibility of its usage as a prognostic molecular biomarker of this disease. The retrospective included 64 adult patients with clear cell RCC (ccRCC) in whom radical or partial nephrectomy was conducted. After deparaffinization of formalin-fixed paraffin-embedded (FFPE) ccRCC specimens, the tissue expression of miR-15a was measured using the reverse transcription and quantitative polymerase chain reaction in the real time. For the reference, the expression of miR-15a was estimated in 15 FFPE tissue specimens of the normal renal parenchyma. Survival analysis involved all cases of non-metastatic RCCs (n = 57). Five-year cancer-specific survival (CSS) was estimated by means of the Kaplan-Meier method and was calculated from the date of surgery to the date of death. Patients with the RCC were characterized by significantly upregulated tumor tissue mean levels of miR-15a compared to the healthy controls: 0.10 +/- 2.62 relative units (RU) versus 4.84E - 03 +/- 3.11E - 03 RU (p < 0.001). Overexpression of miR-15a was strongly associated with poor histologic prognostic features of ccRCC. Poorly differentiated tumors tend to have more pronounced upregulation of miR-15a compared to highly differentiated lesions: Mean expression values were 4.57 +/- 3.19 RU for Fuhrman grade 4 versus 0.02 +/- 0.01 RU for Fuhrman grade 1 (p < 0.001). The metastatic involvement of the regional lymphatic nodules (N +) was associated with significantly upregulated miRNA-15a in comparison with N - cases: Mean expression values were 4.92 +/- 2.80 RU versus 1.10 +/- 2.29 RU, respectively (p < 0.001). In patients with miR-15a expression in RCC tissues <= 0.10 RU, mean 5-year CSS was significantly longer compared to patients with expression levels above this threshold: 92.31% (mean duration of survival-59.88 +/- 0.12 months) versus 54.8% (mean duration of survival-49.74 +/- 2.16 months), respectively (p < 0.001). The tissue expression of miR-15a could be used as a potential prognostic molecular biomarker for conventional RCC.